**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 64264

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm**

Zhou JY *et al*. A machine learning-based algorithm for hepatic inflammation

Ji-Yuan Zhou, Liu-Wei Song, Rong Yuan, Xiao-ping Lu, Gui-Qiang Wang

**Ji-Yuan Zhou,** Department of Gastroenterology, The Second Afﬁliated Hospital of Guangzhou Medical University, Guangzhou 510260, Guangdong Province, China

**Liu-Wei Song,** School of Public Health, Xiamen University, Xiamen 361005, Fujian Province, China

**Rong Yuan, Xiao-Ping Lu,** Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China

**Gui-Qiang Wang,** Department of Infectious Disease, Peking University First Hospital, Beijing 100034, China

**Author contributions:** Zhou Jy designed the study, analyzed the data, and contributed to writing the manuscript; Song Lw and Lu Xp performed the ELISA experiments and contributed to discussions; Yuan R performed the RF-BFE analysis; Wang Gq provided patient data and overall direction; all authors gave final approval of the version to be published and agree to be accountable for all aspects of the work.

**Supported by** theChina Mega-Project for Infectious Diseases, No. 2017ZX10203202; and the Guangdong Basic and Applied Basic Research Foundation, No. 2019A1515110060.

**Corresponding author: Gui-Qiang Wang, MD, Chairman, Director, Professor,** Department of Infectious Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. john131212@126.com

**Received:** February 13, 2021

**Revised:** April 1, 2021

**Accepted:** April 20, 2021

**Published online:** June 7, 2021

**Abstract**

BACKGROUND

Persistent liver inflammatory damage is the main risk factor for developing liver fibrosis, cirrhosis, and even hepatocellular carcinoma in chronic hepatitis B (CHB) patients. Thus, accurate prediction of the degree of liver inflammation is a high priority and a growing medical need.

AIM

to build an effective and robust non-invasive model for predicting hepatitis B-related hepatic inflammation.

METHODS

A total of 650 treatment-naïve CHB (402 HBeAg-positive and 248 HBeAg-negative) patients who underwent liver biopsy were enrolled in this study. Histological inflammation grading was assessed by the Ishak scoring system. Serum quantitative hepatitis B core antibody (qAnti-HBc) levels and 21 immune-related inflammatory factors were measured quantitatively using a chemiluminescent microparticle immunoassay. A backward feature elimination (BFE) algorithm utilizing random forest (RF) was used to select optional features and construct a combined model. The diagnostic abilities of the model or variables were evaluated based on the estimated area under the receiver operating characteristics curve (AUROC) and compared using the DeLong test.

RESULTS

Four features were selected to predict moderate-to-severe inflammation in CHB patients using the RF-BFE method. These predictive features included qAnti-HBc, ALT, AST, and CXCL11. Spearman’s correlation analysis indicated that serum qAnti-HBc, ALT, AST, and CXCL11 levels were positively correlated with the histology activity index (HAI) score. These selected features were incorporated into the model to establish a novel model named I-3A index. The AUROC [0.822; 95% confidence interval (CI): 0.790-0.851] of the I-3A index was significantly increased compared with qAnti-HBc alone (0.760, 95%CI: 0.724-0.792, *p* < 0.0001) in all CHB patients. The use of an I-3A index cutoff value of 0.41 produced a sensitivity of 69.17%, specificity of 81.44%, and accuracy of 73.8%. Additionally, the I-3A index showed significantly improved diagnostic performance for predicting moderate-to-severe inflammation in HBeAg-positive and HBeAg-negative CHB patients (0.829, 95%CI: 0.789-0.865 and 0.810, 95%CI: 0.755-0.857, respectively).

CONCLUSION

The selected features of the I-3A index constructed using the RF-BFE algorithm can effectively predict moderate-to-severe liver inflammation in CHB patients.

**Key Words:** hepatic inflammation; machine learning; quantitative hepatitis B core antibody; CXCL11; diagnostic efficiency

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhou JY, Song LW, Yuan R, Lu XP, Wang GQ. Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm. *World J Gastroenterol* 2021; 27(21): 2910-2920

**URL:** <https://www.wjgnet.com/1007-9327/full/v27/i21/2910.htm>

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i21.2910

**Core Tip:** We aimed to propose an effective backward feature elimination algorithm utilizing random forest to select optimal features and construct a novel non-invasive model for predicting hepatitis B-related hepatic inflammation based on a large, multicenter cohort. The results indicated that the I-3A index constructed based on the selected features significantly improved the diagnostic efficiency of quantitative hepatitis B core antibody alone for predicting moderate-to-severe inflammation. Additionally, the I-3A index showed high diagnostic accuracy for moderate-to-severe inflammation in both HBeAg-positive and HBeAg-negative chronic hepatitis B patients.

**INTRODUCTION**

It is estimated that greater than 257 million people are chronically infected with hepatitis B virus (HBV), and over 880000 deaths are caused by HBV infection annually worldwide due to complications of the disease, such as liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)[[1](#_ENREF_1" \o "Collaborators, 2018 #16405)]. In general, hepatocellular lesions are not caused by HBV directly but are the result of the induction of the body's autoimmune response to inflammatory damage in hepatocytes. The burden of continuous inflammatory injury of hepatocytes not only hinders the body to clear HBV but is also the main risk factor for the development of liver fibrosis, cirrhosis, and even HCC[[2](#_ENREF_2" \o "Berasain, 2009 #16214)]. Thus, it is essential to accurately evaluate the degree of hepatic inflammation and effectively reverse disease progression in chronic hepatitis B (CHB) patients.

Hepatitis B core antibody (anti-HBc) is a specific, nonprotective antibody against hepatitis B core antigen (HBcAg) that can be detected in almost all patients who have been exposed to HBV[[3](#_ENREF_3" \o "Wu, 2017 #16328)]. Recent studies have identified serum quantitative hepatitis B core antibody (qAnti-HBc) levels as an important immunological indicator that reflects immune activation status[[4-7](#_ENREF_4" \o "Fan, 2016 #11860)]. Furthermore, we previously reported that serum qAnti-HBc levels increase significantly with increasing histology activity index (HAI) score and have potential clinical value in assessing the degree of hepatitis B-related hepatic inflammation in CHB patients[[8](#_ENREF_8" \o "Zhou, 2017 #16274)]. However, the optimal diagnostic efficacy may not be obtained by using qAnti-HBc alone, and its combination with other biomarkers potentially offers great clinical application value.

In this study, we aimed to assess the correlation between inflammatory immune-related factors and the degree of liver inflammation in CHB patients. Furthermore, we aimed to establish a novel model of serum qAnti-HBc combined with other immune inflammatory factors using a machine learning strategy to improve the diagnostic efficiency of qAnti-HBc in predicting the degree of hepatitis B-related hepatic inflammation.

**MATERIALS AND METHODS**

***Patients***

Patients with chronic HBV infection were enrolled in this study from 24 hospitals between October 2013 and December 2015. Patients recruited in the cohort study met the following criteria: (1) Age 18-75 years; (2) hepatitis B surface antigen (HBsAg) seropositive status beyond 6 mo; (3) being treatment naïve; (4) serum negative for anti-hepatitis Avirus (HAV) IgM, anti-HCV, anti-hepatitis E virus (HEV) IgM/IgG, anti-Epstein–Barr virus (EBV) IgM, and anti-cytomegalovirus (CMV) IgM; and (5) withdrawal from potential transaminase-lowering agents such as bicyclol for at least 2 wk prior to blood biochemistry analysis.

The exclusion criteria for this study included overlapping etiologies for hepatitis, including HCV, HIV, alcoholism, autoimmune disease, genetic disease, drug-induced causes, and nonalcoholic fatty liver. Patients with decompensated cirrhosis or HCC were also excluded. All patents provided written informed consent for the scientific use of their clinical data and samples. The complete protocol for the clinical trial has been registered at clinicaltrials.gov (NCT01962155) and chictr.org (ChiCTR-DDT-13003724).

***Data acquisition***

All patients underwent ultrasonographic-guided liver biopsy according to a standardized protocol. Pathological interpretations were conducted at the Department of Pathology of Youan Hospital affiliated with Capital Medical University. Each section was blindly and independently assessed by two pathologists. When discrepancies occurred, the samples were reviewed by experienced pathologists who were also responsible for reassessing in 10% of the samples selected randomly. The modified HAI was used to grade disease inflammatory activity. HAI ≥ 5 represented moderate-to-severe inflammation, and fibrosis score ≥ 3 was considered significant fibrosis[[9](#_ENREF_9" \o "Wai, 2003 #16223),[10](#_ENREF_10)].

At the time of liver biopsy, biochemical, blood cell, and coagulation tests were further performed using routine automated analyzers. Serum HBsAg and HBeAg levels were quantified by commercially available enzyme immunoassays (Roche Diagnostics, Penzberg, Germany). Serum HBV DNA levels (range 2.0 × 101-1.7 × 108 IU/mL) were measured *via* a COBAS AmpliPrep/COBAS TaqMan method. Serum qAnti-HBc levels were measured using double-sandwich enzyme-linked immunosorbent assays (Wantai, Xiamen, China).

Six cytokines (CXCL9, CXCL10, CXCL11, IL-2R, IL-33, and IL-34) were measured with a Luminex screening system (LXSAHM-6, R&D, Minneapolis, MN, United States). Additionally, 15 cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, IL-17A, CCL2, CCL3, IL-12 p70, IFN-γ, TNF-α, TGF-α, and granulocyte-monocyte colony stimulating factor) were measured with human cytokines panel I (Cat. No. HCYTOMAG-60K, EMD Millipore, Billerica, MA, United States). The results were analyzed with a Luminex 200 system (EMD Millipore, Billerica, MA, United States) according to the manufacturer’s instructions. The coefficient of variation between the duplicate wells was controlled within 10%, and R2 of the standard curve was at least 0.999.

***Selection of significant features***

In this study, a random forest (RF)-backward feature elimination (BFE) algorithm was used to automatically select the optimal feature subset, and the main procedure of the RF-BFE algorithm is illustrated in Figure 1. First, the entire dataset was shuffled and the features were ranked by RF importance measures. Then, least absolute shrinkage and selection operator (LASSO) regression was iteratively used to perform both regularization and calculation of accuracy in the BFE. LASSO constructs a linear model, which penalizes the regression coefficients with an L1 penalty, shrinking many of them to zero. It performs both variable selection and regularization in order to enhance the prediction accuracy and interpretability of the resulting statistical model. The iterations ended when further removals did not result in an improvement, and produced a series of feature subsets. Finally, all of the feature subsets were gathered in a feature counter, and the final feature subset was determined by hard voting with equal weight.

To provide more robust results, the RF importance measure of each feature was calculated in every iteration. The detailed feature selection scheme in an iteration is illustrated in Figure 2. The least important feature was eliminated, and then the updated features were used to retrain the LASSO regression. The BFE process ended when the accuracy no longer improved. The accuracy was calculated as follows:

*Sensitivity = TP/(TP + FN)*

*Specificity = TN/(TN + FP)*

*Accuracy = (Sensitivity + Specificity)/2* (1)

where TP, TN, FP, and FN represent true positive, true negative, false positive, and false negative, respectively.

In our study, 100 iterations were implemented. Therefore, we used a hard vote strategy to determine the final features after the 100 subsets of the features were obtained. All of the selected features were gathered in a feature counter. The final feature subset *Fs* with *k* features was determined as follows:

*Fs =Fsub* :{*f*1, *f*2, ..., *fk*}|*vf>v*0

*vf ,v0*∈(0,*N*) (2)

where *Fsub* is the set of features addressed in all subsets, *vf* is the vote of the feature, and *v0* is the threshold. Given that we used 100 iterations, *vf* and *v0* ranged from 0 to 100.

***Statistical analysis***

Statistical analyses were conducted with SPSS (version16.0) and Python (version 3.5). Quantitative variables are expressed as the mean ± SD. Student’s *t* test was used to analyze single specific differences of biological interest, and the chi-square test was used to analyze relationships between categorical variables. Spearman’s rank tests were used to analyze associations between features and the HAI score. The LASSO logistic regression was performed using the “glmnet” package. The AUROC of models for diagnosing moderate-to-severe inflammation was analyzed using MedCalc version 15.6 (Ostend, Belgium). The diagnostic abilities of the different models were compared using the DeLong test. Additionally, the sensitivity, specificity, positive predictive value, (PPV) and negative predictive value (NPV) for the cut-off values were calculated. The level of statistical significance was defined as *p* < 0.05 (two-tailed).

**RESULTS**

***Clinical characteristics of the study population***

In this study, a total of 650 patients were included in the statistical analysis, including 402 HBeAg-positive CHB patients and 248 HBeAg-negative CHB patients. Among the HBeAg-positive patients, 248 (61.69%) had at least moderate inflammation, and 249 (61.49%) had significant fibrosis. Among the HBeAg-negative patients, 138 (55.64%) had at least moderate inflammation, and 101 (40.73%) had significant fibrosis. The specific demographic characteristics are shown in Table 1. Serum levels of 4 (IL-2, IL-4, IL-12 p70, and CXCL9) of 21 cytokines were below the limits of detection in CHB patients. The remaining 17 cytokines were detected.

***Features selection and model building***

In this study, we set the threshold *v0* to 100, and four features (qAnti-HBc, ALT, AST, and CXCL11) were selected using the RF-BFE method (Figure 3 and Table 2). To validate the correlation between the selected features and HAI score, Spearman’s rank tests were further performed. In HBeAg-positive patients, serum qAnti-HBc, ALT, AST, and CXCL11 levels were positively correlated with the HAI score (*r* = 0.55, 0.45, 0.51, and 0.34, respectively, *p* < 0.001). In HBeAg-negative patients, serum qAnti-HBc, ALT, AST, and CXCL11 Levels were also positively correlated with the HAI score (*r* = 0.49, 0.44, 0.49, and 0.33, respectively, all *p* < 0.001) (Table 2). Therefore, these selected features were incorporated into model construction to predict moderate-to-severe inflammation. Furthermore, the selected features were normalized using LASSO regression according to the following formula: ALT’ = (ALT-100.1)/130.25; AST’ = (AST-64.28)/78.33; Log(qAnti-HBc)’ = [log(qAnti-HBc) - 4.408]/0.7835; CXCL11’ = (CXCL11-55.02)/68.80. The established model, namely, the I-3A score, was calculated as follows:

Logit *p* = 1/[1+ exp(0.4986 × ALT’ + 1.190 × AST’ + 0.9154 × log(qAnti-HBc)’ + 0.5333 × CXCL11’ + 0.8099)]. (3)

***Predictive performance***

The ROC curves for predicting moderate-to-severe inflammation are shown in Figure 4 and Table 3. In all patients, the AUROC of the I-3A index to differentiate patients with moderate-to-severe inflammation was 0.822 [95% confidence interval (CI): 0.790-0.851], showing a significant increase compared with the value of 0.760 (95%CI: 0.724-0.792) for qAnti-HBc alone (*p* < 0.0001). The use of an I-3A index cutoff value of 0.41 (< 0.41) for predicting moderate-to-severe liver inflammation produced a sensitivity of 69.17%, specificity of 81.44%, and accuracy of 73.8%. The use of a qAnti-HBc cutoff value of 4.20 Log10IU/mL produced a sensitivity of 83.94%, specificity of 55.68%, and accuracy of 72.13% (Table 3). Similar results were obtained in diagnostic efficiency analyses of both in HBeAg-positive and HBeAg-negative CHB patients. Thus, these results indicate that the I-3A index has better diagnostic efficiency for predicting moderate-to-severe inflammation.

**DISCUSSION**

The BFE algorithm is widely used to reduce the dimensionality of feature space and is commonly employed using the support vector machine (SVM). RF is an importance measure that reveals the impact of each variable and has several advantages compared with SVM, as RF is an unbiased estimator, easy to parallel, and effectively and efficiently employed[[11](#_ENREF_11" \o "Breiman, 2001 #16417)]. In this study, we proposed an effective BFE algorithm utilizing RF to select optional features and constructed a novel non-invasive model for predicting the degree of hepatitis B-related hepatic inflammation based on serum qAnti-HBc and other immune inflammatory factors. The results indicated that the I-3A index constructed based on the selected features significantly improved the diagnostic efficiency of qAnti-HBc alone for predicting moderate-to-severe inflammation. Additionally, the I-3A index showed high diagnostic accuracy for moderate-to-severe inflammation in both HBeAg-positive and HBeAg-negative CHB patients (AUROC = 0.829 and 0.810, respectively).

Histological analysis based on liver biopsy is the gold standard for evaluating the severity of hepatic inflammation. However, the practical use of this diagnostic method is limited by the traumatic nature of the procedures, which has inherent risks such as bleeding and sampling error[[12](#_ENREF_12),[13](#_ENREF_13)]. ALT is the most widely used parameter of liver inflammation in clinical practice[[14](#_ENREF_14" \o "Kim, 2008 #16418)]. However, the diagnostic efficiency of ALT is limited due to its poor performance in CHB patients[[15](#_ENREF_15" \o "Chao, 2014 #16222),[16](#_ENREF_16)]. Therefore, non-invasive biomarkers that can accurately assess hepatic inflammation are still urgently needed. Our previous study of large, multicenter cohorts revealed that the serum qAnti-HBc level was remarkably correlated with the degree of liver inflammation in CHB patients[[8](#_ENREF_8" \o "Zhou, 2017 #16274)]. Further analysis indicated that qAnti-HBc was an independent risk factor for moderate-to-severe inflammation in CHB patients and exhibited high diagnostic accuracy for hepatic inflammation in patients with normal ALT levels[[8](#_ENREF_8" \o "Zhou, 2017 #16274)]. A recent study by Chen *et al*[[17](#_ENREF_17" \o "Chen, 2019 #16403)] reported that serum qAnti-HBc levels could reflect the degree of hepatic inflammation in children infected with HBV who have normal ALT levels. Together, these findings suggest that serum qAnti-HBc is a promising biomarker of hepatic inflammation. In this study, the AUROC value of serum qAnti-HBc levels for predicting CHB patients with moderate-to-severe inflammation was 0.760, similar to the value of 0.768 reported by Li *et al*[[18](#_ENREF_18" \o "Li, 2017 #16275)]. To improve the diagnostic efficiency of qAnti-HBc in the CHB population, a combined model was constructed. Li *et al*[[18](#_ENREF_18" \o "Li, 2017 #16275)] reported a novel model (AC index) combing qAnti-HBc and ALT that exhibited improved diagnostic efficiency for predicting patients with moderate-to-severe inflammation with an AUROC of 0.810. In this study, the RF-BFE algorithm was used to evaluate immune inflammatory factors that may be related to the degree of CHB liver inflammation, and the importance of each factor was evaluated. The results showed that in addition to qAnti-HBc, CXCL11, ALT, and AST exhibited relatively high significance in measuring liver inflammation. The AUROC value of the combined I-3A model based on LASSO regression was as high as 0.822, showing a significant increase compared with the diagnostic value of qAnti-HBc alone (LeLong *p* < 0.0001). Furthermore, the AUROC value of the I-3A index was significantly higher than that of the AC index reported by Li *et al*[[18](#_ENREF_18)] (0.822 *vs* 0.810, DeLong *p* =0.041).

Of note, serum CXCL11 levels increased significantly as the HAI score increased in CHB patients. CXCL11, which is also known as human interferon-inducible T cell alpha chemokine (I-TAC), is a member of the chemokine family and is involved in various inflammatory and angiogenic processes[[19](#_ENREF_19)]. In liver disease, hepatocytes and sinusoidal cells release CXCL11, selectively recruit activated T cells to sites of inflammation, and are involved in the progression of hepatic damage[[20](#_ENREF_21" \o "KJ, 2004 #16415)]. In our study, CXCL11 was selected using the RF-BFE method and represents a potential biomarker for predicting moderate-to-severe inflammation in CHB patients. Serum CXCL10 levels were also positively correlated with the severity of histological inflammation, consistent with the findings of previous studies[[21](#_ENREF_22" \o "Zeremski, 2008 #16421),[22](#_ENREF_23)]. However, in our study, CXCL10 was not selected and incorporated into the model. CXCR3 (CD183) is a surface marker of B lymphocyte activation, and its ligands include CXCL10 and CXCL11. Increased CXCR3 expression is observed in chronic viral hepatitis and correlates with increases in CXCL10 and CXCL11 expression[[21](#_ENREF_22" \o "Zeremski, 2008 #16421),[23](#_ENREF_24)]. In our study, serum CXCL10 and CXCL11 levels were positively correlated not only with the degree of liver inflammation but also with the level of serum qAnti-HBc in CHB patients (data not shown). This finding suggests that a large proportion of activated B lymphocytes may be present in CHB patients with hepatic inflammatory injury and that the specific level of qAnti-HBc secreted by B lymphocytes in circulating blood may indirectly reflect the degree of immune inflammatory injury of the liver. However, the specific mechanisms of B lymphocytes, Anti-HBc, and liver immune injury must be further explored.

There are several limitations to our study. First, this study examined only serological inflammatory factors, but imaging techniques or transient elastography may improve performance. Radiomics is a promising tool that extracts high-throughput quantitative features from medical images and can provide valuable information for the diagnosis of liver damage. Second, it was a cross-sectional study and longitudinal data were not obtained to verify our results. Finally, our previous studies reported that qAnti-HBc alone has high diagnostic accuracy for predicting liver inflammation in CHB patients with normal ALT levels, and the I-3A index does not remarkably improve the diagnostic value of qAnti-HBc. Therefore, future prospective studies are needed to achieve increased diagnostic accuracy.

**CONCLUSION**

In conclusion, the selected features of the I-3A index constructed using the RF-BFE method can effectively predict liver inflammation in CHB patients.

**ARTICLE HIGHLIGHTS**

***Research background***

The burden of continuous inflammatory injury of hepatocytes is the main risk factor for the development of liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Thus, it is essential to accurately evaluate the degree of hepatic inflammation and effectively reverse disease progression in chronic hepatitis B (CHB) patients.

***Research motivation***

Recent studies have identified that serum quantitative hepatitis B core antibody (qAnti-HBc) levels have potential clinical value in assessing the degree of hepatitis B-related hepatic inflammation in CHB patients. However, the optimal diagnostic efficacy may not be obtained by using qAnti-HBc alone, and its combination with other biomarkers potentially offers great clinical application value.

***Research objectives***

The objective of this study was to build an effective and robust noninvasive model for predicting hepatitis B-related hepatic inflammation.

***Research methods***

Serum qAnti-HBc levels and 21 immune-related inflammatory factors were measured quantitatively in 650 treatment-naïve CHB patients who underwent liver biopsy. A backward feature elimination (BFE) algorithm utilizing Random Forest (RF) was used to select optional features and construct a combined model. The diagnostic abilities of the model or variables were evaluated based on estimated area under the receiver operating characteristics curve (AUROC) and compared using the DeLong test.

***Research results***

Four features (qAnti-HBc, ALT, AST, and CXCL11) were selected and incorporated into the model to establish a novel I-3A index. The AUROC of the I-3A index to predict moderate-to-severe liver inflammation was significantly increased compared with qAnti-HBc alone in all CHB patients. The I-3A index showed significantly improved diagnostic performance for predicting moderate-to-severe inflammation in HBeAg-positive and HBeAg-negative CHB patients.

***Research conclusions***

The selected features of the I-3A index constructed using the RF-BFE algorithm can effectively predict moderate-to-severe liver inflammation in CHB patients.

***Research perspectives***

The novel I-3A index is a promising non-invasive tool to predict liver inflammation. A longitudinal study is needed to verify our results and more emerging strategies such as radiomics are needed to further achieve increased diagnostic efficiency.

**REFERENCES**

1 **Polaris Observatory Collaborators**. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol* 2018; **3**: 383-403 [PMID: 29599078 DOI: 10.1016/S2468-1253(18)30056-6]

2 **Berasain C**, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links . *Ann N Y Acad Sci* 2009; **1155**: 206-221 [PMID: 19250206 DOI: 10.1111/j.1749-6632.2009.03704.x]

3 **Wu T**, Kwok RM, Tran TT. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. *Am J Gastroenterol* 2017; **112**: 1780-1788 [PMID: 29087395 DOI: 10.1038/ajg.2017.397]

4 **Fan R**, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. *Gut* 2016; **65**: 313-320 [PMID: 25586058 DOI: 10.1136/gutjnl-2014-308546]

5 **Song LW**, Liu PG, Liu CJ, Zhang TY, Cheng XD, Wu HL, Yang HC, Hao XK, Yuan Q, Zhang J, Kao JH, Chen DS, Chen PJ, Xia NS. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. *Clin Microbiol Infect* 2015; **21**: 197-203 [PMID: 25658546 DOI: 10.1016/j.cmi.2014.10.002]

6 **Yang HC**, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. *J Hepatol* 2018; **69**: 286-292 [PMID: 29551710 DOI: 10.1016/j.jhep.2018.02.033]

7 **Chi H**, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. *Clin Gastroenterol Hepatol* 2019; **17**: 182-191.e1 [PMID: 29902645 DOI: 10.1016/j.cgh.2018.05.047]

8 **Zhou J**, Song L, Zhao H, Yan L, Ma A, Xie S, Zhang X, Zhang D, Xie Q, Zhang G, Shang J, Cheng J, Zhao W, Zou Z, Zhang M, Xia N, Wang G. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. *Sci Rep* 2017; **7**: 2747 [PMID: 28584279 DOI: 10.1038/s41598-017-03102-3]

9 **Wai CT**, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; **38**: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]

10 **Hui AY**, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. *Am J Gastroenterol* 2005; **100**: 616-623 [PMID: 15743360 DOI: 10.1111/j.1572-0241.2005.41289.x]

11 **Breiman L**. Random Forests. *Mach Learn* 2001; **45**: 5-32 [DOI: 10.1023/A:1010933404324]

12 **Cadranel JF**, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). *Hepatology* 2000; **32**: 477-481 [PMID: 10960438 DOI: 10.1053/jhep.2000.16602]

13 **Regev A**, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002; **97**: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]

14 **Kim WR**, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. *Hepatology* 2008; **47**: 1363-1370 [PMID: 18366115 DOI: 10.1002/hep.22109]

15 **Chao DT**, Lim JK, Ayoub WS, Nguyen LH, Nguyen MH. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. *Aliment Pharmacol Ther* 2014; **39**: 349-358 [PMID: 24387289 DOI: 10.1111/apt.12590]

16 **Sarin SK**, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016; **10**: 1-98 [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4]

17 **Chen HS**, Wu JF, Su TH, Chen HL, Hsu HY, Xia NS, Chen PJ, Chang MH. Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level. *Hepatology* 2019; **70**: 1903-1912 [PMID: 31121067 DOI: 10.1002/hep.30788]

18 **Li J**, Zhang TY, Song LW, Qi X, Yu XP, Li FH, Zhou P, Qin YL, Yang L, Zhao JH, Mao RC, Zhang YM, Wang JY, Yang FF, Zhu HX, Yang SS, Huang YX, Yuan Q, Zhang J, Zhang JM, Xia NS. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. *Hepatol Res* 2018; **48**: E133-E145 [PMID: 28707778 DOI: 10.1111/hepr.12937]

19 **Lacotte S**, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. *Ann N Y Acad Sci* 2009; **1173**: 310-317 [PMID: 19758167 DOI: 10.1111/j.1749-6632.2009.04813.x]

20 **Helbig KJ**, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. *Hepatology* 2004; **39**: 1220-1229 [PMID: 15122750 DOI: 10.1002/hep.20167]

21 **Zeremski M**, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. *Hepatology* 2008; **48**: 1440-1450 [PMID: 18798334 DOI: 10.1002/hep.22500]

22 **Chalin A**, Lefevre B, Devisme C, Barget N, Amiot L, Samson M. Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection. *Cytokine* 2019; **117**: 72-78 [PMID: 30826602 DOI: 10.1016/j.cyto.2019.02.006]

23 **Butera D**, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. *Blood* 2005; **106**: 1175-1182 [PMID: 15860662 DOI: 10.1182/blood-2005-01-0126]

**Footnotes**

**Institutional review board statement:** The study was approved by the Human Research Committee of Peking University First Hospital.

**Informed consent statement:** All patients gave informed consent.

**Conflict-of-interest statement:** No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of item.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 13, 2021

**First decision:** March 14, 2021

**Article in press:** April 20, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Sujatha R **S-Editor:** Gong ZM **L-Editor:** Wang TQ **P-Editor:** Wang LL


**Figure Legends**




**Figure 1 The main procedure of the random forest-backward feature elimination algorithm.** BFE: backward feature elimination; LASSO: least absolute shrinkage and selection operator.



**Figure 2 Feature selection scheme in an iteration.** LASSO: least absolute shrinkage and selection operator.



**Figure 3Histogram of the votes in the feature counter.** BMI: body mass index; HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TC: total cholesterol; TBil: total bilirubin; DBil: direct bilirubin; PT: prothrombin time; Cr: creatinine; BUN: blood urea nitrogen; qAnti-HBc: quantitative hepatitis B core antibody; IL: interleukin, IFN: interferon; TNF: tumor necrosis factor; TGF: transforming growth factor.



**Figure 4 Receiver operating characteristic curve analysis for predicting moderate-to-severe inflammation in all patients with chronic hepatitis B virus infection, HBeAg-positive patients with chronic hepatitis B virus infection, and HBeAg-negative patients with chronic hepatitis B virus infection.** A: All patients with chronic hepatitis B virus infection; B: HBeAg-positive patients with chronic hepatitis B virus infection; C: HBeAg-negative patients with chronic hepatitis B virus infection. AUROC: area under the receiver operating characteristics curve; CI: confidence interval; qAnti-HBc: quantitative hepatitis B core antibody.

**Table 1 Clinical characteristics of patients with chronic hepatitis B virus infection**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **HBeAg-positive patients (*n* = 402)** | **HBeAg-negative patients (*n* = 248)** | ***P* value** |
| Gender, male | 79.4.4% (319/402) | 76.2% (189/248) | 0.38 |
| Age (yr) | 36.35 ± 10.36 | 41.67 ± 9.65 | < 0.001 |
| BMI (kg/m2) | 23.12 ± 3.31 | 23.62 ± 2.84 | 0.01 |
| HBsAg (log10 IU/mL) | 3.83 ± 0.81 | 3.16 ± 0.73 | < 0.001 |
| HBV DNA (log10IU/mL) | 6.93 ± 1.66 | 4.82 ± 1.64 | < 0.001 |
| ALT (U/L) | 106.74 ± 139.40 | 80.58 ± 105.61 | < 0.001 |
| AST (U/L) | 65.48 ± 78.67 | 56.69 ± 70.06 | 0.029 |
| TC (mmol/L) | 4.61 ± 3.05 | 4.44 ± 0.98 | 0.691 |
| TBil (μmol/L) | 16.54 ± 15.48 | 18.49 ± 27.32 | 0.009 |
| DBil (μmol/L) | 5.61 ± 7.54 | 5.77 ± 6.59 | 0.527 |
| Albumin (g/L) | 43.72 ± 5.14 | 44.91 ± 6.07 | 0.011 |
| PT (s) | 12.81 ± 1.49 | 12.55 ± 1.49 | 0.035 |
| Cr (μmol/L) | 70.21 ± 25.41 | 69.19 ± 15.93 | 0.818 |
| BUN (mmol/L) | 5.28 ± 5.57 | 4.90 ± 1.33 | 0.681 |
| Platelet counts (× 109/L) | 178.6 ± 56.18 | 158.5 ± 55.28 | < 0.001 |
| Histology (*n*, %) |  |  |  |
| HAI 0-4 | 38.31% (154/402) | 44.35% (110/248) | 0.14 |
| HAI ≥ 5 | 61.69% (248/402) | 55.64% (138/248) |  |
| fibrosis score 0-2 | 38.06% (153/402) | 59.27% (147/248) | < 0.001 |
| fibrosis score ≥ 3 | 61.49% (249/402) | 40.73% (101/248) |  |

BMI: body mass index; HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TC: total cholesterol; TBil: total bilirubin; DBil: direct bilirubin; PT: prothrombin time; Cr: creatinine; BUN: blood urea nitrogen; HAI: histology activity index.

**Table 2 Selected features for predicting moderate-to-severe inflammation in patients with chronic hepatitis B virus infection (more than 40 votes)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Feature name** | **HBeAg-positive patients** | | | **HBeAg-negative patients** | | |
| **Votes** | ***Spearman’r* (95%CI)**1 | ***P* value1** | **Votes** | **Spearman *r* (95%CI)**1 | ***P* value**1 |
| ALT | 100 | 0.45 (0.36-0.53) | < 0.001 | 100 | 0.44 (0.33-0.53) | < 0.001 |
| AST | 100 | 0.51 (0.43-0.58) | < 0.001 | 100 | 0.49 (0.38-0.58) | < 0.001 |
| qAnti-HBc | 100 | 0.55 (0.47-0.62) | < 0.001 | 100 | 0.49 (0.39-0.58) | < 0.001 |
| CXCL10 | 46 | 0.34 (0.25-0.43) | < 0.001 | 51 | 0.35 (0.23-0.46) | < 0.001 |
| CXCL11 | 100 | 0.34 (0.25-0.43) | < 0.001 | 100 | 0.33 (0.21-0.44) | < 0.001 |
| IL-2R | 71 | 0.30 (0.20-0.39) | < 0.001 | 44 | 0.27 (0.14-0.38) | < 0.001 |
| CCL2 | 42 | -0.01 (-0.09-0.07) | 0.79 | 52 | 0.03 (-0.10-0.16) | 0.65 |
| TNF-α | 56 | 0.01 (-0.17-0.09) | 0.78 | 62 | 0.01 (-0.17-0.09) | 0.78 |
| IL-1β | 27 | -0.10 (-0.23-0.03) | 0.12 | 54 | 0.15 (0.03-0.28) | 0.02 |

1Correlation between features and scores of histological activity in patients with chronic hepatitis B virus infection. ALT: alanine aminotransferase; AST: aspartate aminotransferase; qAnti-HBc: quantitative hepatitis B core antibody; IL: interleukin; TNF: tumor necrosis factor; CI: confidence interval.

**Table 3 Receiver operating characteristic curve analysis of inflammation scores in patients with chronic hepatitis B virus infection**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Cutoff value** | **Se (%)** | **Spe (%)** | **PPV (%)** | **NPV (%)** | **Accuracy (%)** | **AUROC (95%CI)** | ***P* value** |
| **All patients** | | | | | | | | |
| I-3A | < 0.41 | 69.17 | 81.44 | 84.49 | 64.37 | 73.8 | 0.82 (0.79-0.85) | < 0.0001 |
| qAnti-HBc | > 4.20 log10 IU/ml | 83.94 | 55.68 | 73.47 | 70.33 | 72.13 | 0.76 (0.72-0.79) |  |
| **HBeAg-positive patients** | | | | | | | | |
| I-3A | < 0.41 | 70.16 | 80.52 | 85.29 | 62.63 | 74.13 | 0.83 (0.79-0.87) | < 0.0001 |
| qAnti-HBc | > 4.20 log10 IU/ml | 83.06 | 60.39 | 77.15 | 68.89 | 74.38 | 0.77 (0.73-0.81) |
| **HBeAg-negative patients** | | | | | | | | |
| I-3A | < 0.44 | 73.19 | 78.18 | 80.8 | 69.92 | 75.4 | 0.81 (0.76-0.86) | 0.002 |
| qAnti-HBc | > 4.40 log10 IU/ml | 76.81 | 61.13 | 71.62 | 68 | 70.16 | 0.75 (0.70-0.81) |

Se: sensitivity; Spe: specificity; PPV: positive predictive value; NPV: negative predictive value; AUROC: area under the receiver operating characteristics curve; CI: confidence interval; HBeAg: hepatitis B e antigen; qAnti-HBc: quantitative hepatitis B core antibody.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**